DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 408 - Related articles - All 10 versions
- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent
insulin secretion. Both peptides also regulate β-cell proliferation and ... Cited by 283 - Related articles - All 13 versions
- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility
and acid secretion, epithelial integrity, and both nutrient absorption and
disposal. These actions are initiated by activation of specific G protein- ... Cited by 216 - Related articles - BL Direct - All 7 versions
- ►januvia.se [PDF] - Free from Publisher B Charbonnel, A Karasik, J Liu, M Wu, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a
metformin dose titration/stabilization period, and a 2-week, single-blind,
placebo run-in period, 701 patients, aged 19–78 years, with mild to ... Cited by 202 - Related articles - BL Direct - All 9 versions
- ►infekt.ch [PDF] - Free from Publisher P Aschner, MS Kipnes, JK Lunceford, M … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Sitagliptin 100 and 200 mg produced significant (P < 0.001)
placebo-subtracted reductions in A1C (−0.79 and −0.94%, respectively) and
fasting plasma glucose (−1.0 mmol/l [−17.1 mg/dl] and −1.2 mmol/l ... Cited by 194 - Related articles - BL Direct - All 13 versions
- ►januvia.se [PDF] I Raz, M Hanefeld, L Xu, C Caria, D Williams … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis The aim of this study was to assess the efficacy and
safety of sitagliptin (MK-0431) as mono- therapy in patients with type 2
diabetes mellitus and inadequate glycaemic control (HbA 1c Q7% and e10%) on ... Cited by 164 - Related articles - All 5 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org J Mu, J Woods, YP Zhou, RS Roy, Z Li, E … - Diabetes, 2006 - Am Diabetes Assoc Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of
incretin hormones, exert antihyperglycemic effects in type 2 diabetic patients.
A major unanswered question concerns the potential ability of DPP-4 ... Cited by 126 - Related articles - BL Direct - All 9 versions
GA Herman, C Stevens, K Van Dyck, A … - Clinical Pharmacology & Therapeutics, 2005 - nature.com Background: Sitagliptin (MK-0431 [(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[
1,2,4]triazolo[4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine])
is an orally active, potent, and selective inhibitor of dipeptidyl ... Cited by 115 - Related articles - All 6 versions
CF Deacon, B Ahrén, JJ Holst - eid, 2004 - informahealthcare.com Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing
interest to both diabetologists and the pharmaceutical industry alike, as they
may become established as the next member of the oral antidiabetic class of ... Cited by 102 - Related articles - All 7 versions
